Irvine, CA (PRWEB) September 10, 2013
PUR Biologics, LLC, a joint venture focused on the emerging field of biologics for musculoskeletal conditions, including spine, dental and medical device applications, today announced that the United States Patent & Trademark Office has issued two patents covering the multipotent stem cell-derived material utilized by PUR, and its applications in the repair and regeneration of tissue.
The US Patent & Trademark Office issued patent 8,524,494, entitled “Low Oxygen Tension and bFGF Generates a Multipotent Stem Cell from a Fibroblast In Vitro”, and patent 8,530,415, entitled “Repair and/or Regeneration of Cells with a Composition Produced by Culturing Fibroblast Cells under Hypoxic Conditions”, to PUR’s joint venture partner, Histogen, Inc., on September 3 and September 9, 2013, respectively.
The issued patents cover Histogen’s novel technology which triggers the de-differentiation of fibroblast cells into multipotent stem cells through low oxygen and special culture conditions, as well as methods of inducing tissue repair and regeneration by contacting cells with the naturally-secreted multipotent cell conditioned media (CCM) and extracellular matrix (ECM) materials.
“These novel multipotent cell-derived materials hold tremendous potential in orthopedic applications, where we seek to regenerate musculoskeletal tissues and support stem cell growth,” said Ryan Fernan, CEO of PUR Biologics. “Particularly exciting to us is the ability of the material to induce angiogenesis, which is not addressed with currently available orthopedic products.”
Unlike other stem cell-derived therapies, Histogen’s process uniquely begins with newborn fibroblast cells, a safe, well-established and non-controversial cell source, and converts the cells into multipotent stem cells without genetic manipulation. PUR Biologics is currently researching and developing products based u
Copyright©2012 Vocus, Inc.
All rights reserved